It’s by creating and sustaining this culture that we are able to help unlock the power of what science can do.
We have a unique R&D culture where people with curious minds are inspired to think creatively. At the same time, we are harnessing data and technology to fast-forward the pace of our science. It is a culture where people are able to work seamlessly and inclusively together, where all doors are open, talent and diversity are celebrated, and every voice is heard. In addition, we are always learning from people who live with the diseases our medicines treat so we can understand their needs and make sure that great science born in the lab can make a real difference to their lives.
Focusing on quality, not quantity
Empowering the next generation of science leaders
Making our science sustainable
Keeping doors and our minds open
Two organizations. One aim.
Transformative science
R&D Spending
Research and Development (R&D) is crucial for the growth and future success of research-based pharma companies. To maintain their R&D organisations efficient, pharmaceutical companies started to hedge the potential of open innovation to cut R&D costs and to access external knowledge. These new strategies could be divided into several categories: open source, innovation centres, crowd sourcing and virtual R&D.
R&D spending in the pharmaceutical industry covers a variety of activities, including the following:
Invention, or research and discovery of new drugs;
Development, or clinical testing, preparation and submission of applications for FDA approval, and design of production processes for new drugs;
Incremental innovation, including the development of new dosages and delivery mechanisms for existing drugs and the testing of those drugs for additional indications;
Product differentiation, or the clinical testing of a new drug against an existing rival drug to show that the new drug is superior;
Safety monitoring, or clinical trials (conducted after a drug has reached the market) that the FDA may require to detect side effects that may not have been observed in shorter trials when the drug was in development.